Glycobiology and drug design
Author(s)
Bibliographic Information
Glycobiology and drug design
（ACS symposium series, 1102）
American Chemical Society , Distributed in print by Oxford University Press, c2012
Available at 3 libraries
Note
Includes bibliographical references and index
Description and Table of Contents
Description
During the past several years, it has become increasingly clear that carbohydrates, which can be targeted to specific diseases, represent a whole new dimension in drug design. Characterized by a variety of terms - specific recognition, lectins, and molecular diversity, just to cite a few - this new dimension based on carbohydrates essentially has introduced a new language to chemistry, biochemistry, and related disciplines. Vocabulary has been building so fast, in
fact, that most professional chemists (i.e., practitioners who are among the few who work in the area of carbohydrates) may sometimes feel a bit illiterate. This book will help them and many other scientists to better understand the current state of the art and the challenges that remain in
successfully consummating matches of carbohydrate-based drugs and the deadly diseases they target. This book includes preclinical studies and clinical trials of carbohydrate-based drugs in progress as well as analyzing their delivery, biocompatibility, clearance, and metabolic pathways. Further, this book explores a number of other features of carbohydrate drugs and their targets, such as the structure of antibodies with unusually high-affinity for carbohydrates, and protein-glycan interactions
and their inhibitors. Galactomannans and thio-, imino-, nitro-, and aminosugars are particularly considered with respect to their structural and functional impacts. This volume will not only update existing publications on carbohydrate-based drug design but also further shape the emerging data and
thinking in this new area.
Table of Contents
- Preface
- Overview
- 1. Carbohydrates and Drug Design
- Anatole A. Klyosov
- Targeted Drug Design
- 2. Galectin-Targeted Drug Design
- Anatole A. Klyosov
- Cancer
- 3. Development of a Galactomannan Polysaccharide as a Vehicle To Improve the Efficacy of Chemotherapeutics
- Eliezer Zomer, Anatole A. Klyosov, and David Platt
- 4. DAVANAT(R) (GM-CT-01) and Colon Cancer: Preclinical and Clinical (Phase I and II) Studies
- Anatole Klyosov, Eliezer Zomer, and David Platt
- 5. Synthesis and Biological Activity of Galactomycin and DoxoDavanat, New Conjugates of Doxorubicin with D-Galactose and 1,4-?-DGalactomannan
- Anna N. Tevyashova, Anatole A. Klyosov, Eugenia N. Olsufyeva, Maria N. Preobrazhenskaya, and Eliezer Zomer
- Human Immunodeficiency Virus
- 6. Carbohydrate-Based Vaccines against HIV/AIDS
- Lai-Xi Wang
- 7. Toward a Carbohydrate-Based HIV-1 Vaccine
- Leopold Kong, Jean-Philippe Julien, Daniel Calarese, Christopher Scanlan, Hing-Ken Lee, Pauline Rudd, Chi-Huey Wong, Raymond A. Dwek, Dennis R. Burton, and Ian A. Wilson
- Pathogen Management
- 8. Cationic Polysaccharides in the Treatment of Pathogenic Candida Infections
- Avital Mazar Ben-Josef, David Platt, and Eliezer Zomer
- New Approaches in Synthesis and Computational Studies
- 9. Synthetic Methods To Incorporate ?-Linked 2-Amino-2-Deoxy-DGlucopyranoside and 2-Amino-2-Deoxy-D-Galactopyranoside Residues into Glycoconjugate Structures
- Robert J. Kerns and Peng Wei
- 10. Systematic Synthesis of Aminosugars and Their Stereoselective Glycosylation
- Jinhua Wang and Cheng-Wei Tom Chang
- 11. Practical Applications of Computational Studies of the Glycosylation Reaction
- Dennis M. Whitfield and Tomoo Nukada
- Editor's Biography
- Indexes
- Author Index
- Subject Index
by "Nielsen BookData"